Actinium Pharmaceuticals (Delaware) (ATNM) vs Grace Therapeutics (GRCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Grace Therapeutics (GRCE) over the past year, losing 21.1% versus a loss of 46.4%. Over five years, GRCE leads with a -79.3% price change compared with -85.6% for ATNM. Grace Therapeutics is the larger company by market cap ($36.0 million vs $33.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | GRCE |
|---|---|---|
| Share price | $1.05 | $1.71 |
| Market cap | $33.01M | $35.97M |
| 1-day change | -1.87% | -0.58% |
| YTD return | -22.79% | -50.58% |
| 1-year return | -21.05% | -46.39% |
| 5-year return | -85.60% | -79.35% |
| P/E ratio (TTM) | 2.44 | — |
| EPS (TTM) | $0.43 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.00K | — |
| Net income (latest FY) | $-33.89M | $-7.79M |
| Operating margin | -40274.44% | — |
| Net margin | -37652.22% | — |
| 52-week high | $1.72 | $5.18 |
| 52-week low | $0.735 | $1.64 |
| Distance from 52-week high | -38.95% | -66.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +242.86% | +243.27% |
| Average volume | 193.83K | 119.27K |
| Shares outstanding | 31.44M | 21.04M |
| Employees | 27 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed GRCE by 25.3 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ATNM vs GRCE FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Grace Therapeutics?
Grace Therapeutics (GRCE) is larger, with a market capitalization of $35.97M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or GRCE?
ATNM returned -21.05% over the past 12 months, compared with -46.39% for GRCE (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Grace Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.